meta|COVID-19
  • Dynamic meta-analysis of evidences about drug efficacy and safety
  • adjuvant therapies
  • anti-inflammatoty and immuno-therapy
  • antiandrogenic
  • antiviral and associated therapy
  • ASC09/ritonavir
  • azithromycin
  • azvudine
  • baloxavir marboxil
  • carrimycin
  • chloroquine and derivatives
  • chloroquine
  • hydroxychloroquine
  • danoprevir / ritonavir
  • darunavir cobicistat
  • darunavir/cobicistat plus chloroquine
  • doxycycline
  • favipiravir
  • fluvoxamine
  • hydroxychloroquine plus macrolides
  • ivermectin
  • leronlimab
  • lopinavir / ritonavir plus ribavirin
  • lopinavir/ritonavir
  • lopinavir/ritonavir plus chloroquine
  • lopinavir/ritonavir plus interferon ß-1a
  • lopinavir/ritonavir, ribavirin and interferon beta-1b
  • meplazumab
  • nitazoxanide
  • oseltamivir
  • oseltamivir plus chloroquin
  • remdesivir
  • Renin-angiotensin-system-acting agents
  • angiotensin converting enzyme inhibitors (ACEIs)
  • angiotensin receptor blockers (ARBs)
  • angiotensin-(1-7)
  • discontinuation of ACEI/ARB
  • RAS blocker withdrawal
  • rhACE2
  • ribavirin
  • ritonavir
  • sofosbuvir and daclatasvir
  • tenofovir/emtricitabine
  • tenofovir/emtricitabine plus hydroxychloroquine
  • tranexamic acid
  • triazavirin
  • umifenovir (arbidol)
  • control
  • honey
  • miscellaneous
  • vaccines
  • COVID-19
  • COVID 19 hospitalized
  • COVID 19 all comers
  • COVID-19 mild to moderate
  • COVID-19 severe or critically
  • COVID 19 outpatients
  • COVID-19 prophylaxis
  • infections other than COVID-19
  • preventing respiratory virus transmission